Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
0Activity
0 of .
Results for:
No results containing your search query
P. 1
Diabetes Market 26 Billion Dollars and Escalating

Diabetes Market 26 Billion Dollars and Escalating

Ratings: (0)|Views: 8 |Likes:
Published by Josephine Jenno
Insights and Opportunities for Investment in Diabetes Market
www.marketsenus.com
Insights and Opportunities for Investment in Diabetes Market
www.marketsenus.com

More info:

Published by: Josephine Jenno on Feb 03, 2012
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

12/30/2012

pdf

text

original

 
 
Marketsenus.com is a platform for accessing deep business intelligence in 8 industry verticals. Quality 
market research, intelligence and insight (“market information”) impacts a firm’s potential success in a new 
or existing market most when it is actionable and timely. Real research, real time, real actionable insights.
www.Marketsensus.com 
Diabetes – Costs Over 4 Million Lives and 26Billion
 
Dollars
 
Diabetesmellitus, often simply referred to asdiabetes, is a group of metabolic diseases in which a person has high levels of blood sugar, either because the body does not produce enough insulinor because cells do not respond to the insulin that is produced.This high blood sugar produces the classic symptoms of polyuria (frequent urination), polydipsia(increased thirst) and polyphagia (increased hunger).Diabetesis the fifth most common diseasein the world after malaria, tuberculosis, common cold and cancer and is one of the biggest causesof premature illness and death worldwide. It was estimated that approximately four millionpeople died of diabetesin 2010. This is largely due to a 29% increase in the number of deathsdue todiabetesin the North America and Caribbean Region.There are two main types of diabetes.Type 1 diabetesresults from
the body’s failure to produce
insulin and requires manual injection of insulin by the patient. It is also referred to as insulin-dependentdiabetes mellitus(IDDM). Type 2 diabetes results from insulin resistance, a conditionin which cells fail to use insulin properly, sometimes combined with an absolute insulindeficiency. It was formerly referred to as non-insulin-dependentdiabetes mellitus(NIDDM).
The number of sufferers is expected to grow to 438 millionby 2030, corresponding to 7.8% of the adult population
 
The number of sufferers is expected to grow to 438 million by 2030, corresponding to 7.8% of the adult population. While the global prevalence of diabetesis 6.4%, prevalence varies widelyaccording to region. It is high in the Western Pacific region at 10.2% of the total adult populationbut lowest in the African region where it affects 3.8% of the total adult population but isexpected to increase fastest in the future. The primary driver of the diabetes epidemic is the rapidepidemiological shift associated with significant changes in lifestyle including changes in dietarypatterns and decreased physical activity, leading to a higher prevalence of diabetesin the urbanpopulation.Diabetes is one of the most costly health problems in the world. Healthcare expenditure ondiabetesaccounted for 11.6% of the total healthcare expenditure worldwide in 2010. Diabetesalso imposes large economic burdens in the form of lost productivity and foregone economic
 
 
Marketsenus.com is a platform for accessing deep business intelligence in 8 industry verticals. Quality 
market research, intelligence and insight (“market information”) impacts a firm’s potential success in a new 
or existing market most when it is actionable and timely. Real research, real time, real actionable insights.
www.Marketsensus.com 
growth. The American Diabetes Association estimated that the US economy lost $58 billion,approximately half of the direct healthcare expenditure ondiabetesin 2007, because of lostearningsdue to lost work days, restricted activity days, lower productivity at work, mortality andpermanent disability caused by diabetes.
Treatments
 The main goals of diabetes treatments are to keepblood glucoselevels under control and toprevent long-term complications. Diet and exercise, oral hypoglycemic agents, insulin and GLP-1 (glucagon like peptides) agonists are the major options available for the treatment of type 2diabetes. The treatment options are chosen either individually or in combination depending onstage and severity. Diet and exercise are also critically important as 95% of patients with type 2diabetes are obese, a major risk factor for the disease. Obese peoples are at five times more risk of diabetes than those who are a normal weight. For this reason, major pharmaceuticalcompanies focus their biomedical research on the monitoring, control, and treatment of diabetesmellitusand its complications. There has been a significant increase in number of playersinvolved indiabetes researchover the last five years. Drug makers are also more focused onmetabolic disease as it represents one of the largest areas of unmet need in medicine with hugemarket opportunities and is increasing with the obesity epidemic.
The American Diabetes Association estimated that the USeconomy lost $58 billion, approximately half of the directhealthcare expenditure on diabetes
 
Currently available treatment options meet desired efficacy levels but the market has unmetneeds in terms of safety and patient compliance. This implies that the market is moderatelyserved by the current treatment options and that significant potential exists for new entrants.Glitazones, a type of oral anti-diabetic drug, were found to lead to cardiovascular risks indiabetespatients. In 2000, Rezulin (troglitazone), which treated more than 2 million diabetespatients, was found to cause severe side effects such as liver damage and heart problems. Thedrug was pulled from the market on March 21, 2000, following a request from the US FDA.In 2007, Avandia (rosiglitazone), marketed by GlaxoSmithKline, treated more than 6 milliondiabetic patients and brought in more than $1.8 billion in revenue. However, sales declinedsharply after studies discovered that Avandia had been associated with a 40% increase in severeheart risks, congestive heart failure and osteoporosis. According to Sen. Charles Grassley (R-Iowa), approximately 100,000 heart attacks may have been linked to Avandia. Following areview of the data, in September 2010 the European Medicines Agency asked GlaxoSmithklineto withdraw Avandia from the European market and the US FDA asked for it to be used in arestricted class of patients with a new warning.
 
 
Marketsenus.com is a platform for accessing deep business intelligence in 8 industry verticals. Quality 
market research, intelligence and insight (“market information”) impacts a firm’s potential success in a new 
or existing market most when it is actionable and timely. Real research, real time, real actionable insights.
www.Marketsensus.com 
The FDA also issued a black box warning to another TZD class drug Actos (pioglitazonehydrochloride) about the serious risk of adverse cardiovascular events including heart attacks,heart failure and cardiovascular-related deaths. Actos was finally withdrawn from most of themajor markets due to its association with an increased risk of bladder cancer. Unmet need alsoexists in term of insulin delivery systems which currently carry poor patient compliance.Diabetesis a self-managed condition for which the dosage regimen can become confusing,resulting in poor patient compliance and reduced utilization of medication. In addition diabeticpatients have to make decisions about their daily diet, lifestyle, exercise and insulin regime inrelation to self-monitored blood glucose levels. This means that there is a need for insulindelivery systems that can be customized for a specific individual due to differing insulin speedsand durations of action.Insulin analogs such as Lantus have been found to have carcinogenic effects. Diabetic patientsusing insulin analogs were found to contract long-term complications including a risk of cancer.Many insulin analogs act in a similar way to normal human insulin but differ in their biologicaleffect and lead to unknown consequences such as mitogenicity, apoptosis, glucose and lipidmetabolism, and protein degradation.Current competition in the type 2 diabetes market is strong. Many of the older oral hypoglycemicagents which are essentially restricted for use in type 2 diabetics are now available in genericform. In 2010, metfomin, a gold standard treatment fortype 2 diabetes, was one of the mostprescribed and preferred medications used alone or in combination with other products. Theother classes of oral hypoglycemic are also widely available as generic agents, such assulphonylureas and alpha glycosidase inhibitors. However, there has recently been an increase inthe use of combination products as many patients require treatment with multiple drugs. Themost popular combinations are those containing metformin such as Actoplus Met, Janumet andAvandamet.There has also been an increased acceptance of newer agents that target the incretin pathwaysuch as injectable agonists that activate GLP-1 receptors and DPP IV inhibitors that inhibit thepeptidase that deactivates GLP-1. This has led to revenue growth in the diabetes market due tobetter efficacy and safety profiles. Two GLP-1 agonists are currently approved for use: exenatide(Byetta) and liraglutide (Victoza), which are preferred for use in combination with other oraldiabetic agents. The patents of some key established molecules are set to expire between 2012and 2017, including Humalog and Lantus. However, the impact of the patent expiry of thesedrugs will be offset by the expected launch of new products.

You're Reading a Free Preview

Download
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->